Jupiter Neurosciences Reports $42,897 Revenue and $4.3M Net Loss for Six Months Ended June 30, 2026

Jupiter Neurosciences, Inc. reported its financial results for the six months ended June 30, 2026, revealing a net revenue of $42,897, a significant increase from zero revenue in the same period last year. The company incurred a net loss of $4,336,355, compared to a loss of $3,781,832 in the prior year. The increase in losses is attributed to higher general and administrative expenses, which rose by 45% to $3,729,897, driven by increased payroll, consulting, and public relations costs. Research and development expenses decreased by 18% to $1,011,402, reflecting reduced clinical trial and consulting costs.

The company’s total assets decreased to $3,718,600 as of June 30, 2026, down from $5,564,030 at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $1,521,874 from $3,789,342. Current liabilities also decreased significantly from $7,395,882 to $4,084,566, largely due to the fair value of convertible notes payable dropping from $5,298,068 to $1,528,469. The company’s accumulated deficit increased to $39,003,381, raising concerns about its ability to continue as a going concern.

Strategically, Jupiter Neurosciences has made notable advancements, including the launch of its Nugevia product line, which focuses on consumer health and wellness. The company also entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for exclusive U.S. rights to ALA-002, a proprietary MDMA formulation. This agreement includes an upfront payment of $3.33 million and potential milestone payments totaling up to $96.67 million, contingent on development and commercialization achievements.

Operationally, the company is focusing on expanding its market presence, particularly in Asia, where it has established service agreements to facilitate product development and distribution. The company’s workforce has also seen changes, with the appointment of Alison Silva as Chief Operating Officer and President, reflecting a strategic shift in leadership to support its growth initiatives. As of June 30, 2026, the company had 664,670 shares of common stock outstanding, following a reverse stock split effective August 6, 2026, aimed at regaining compliance with Nasdaq listing requirements.

Looking ahead, Jupiter Neurosciences plans to utilize its Standby Equity Purchase Agreement to raise additional capital, with approximately $17.2 million remaining available under the agreement. However, the company acknowledges that its ability to access these funds is contingent on market conditions and trading volume. Management has expressed concerns regarding its liquidity and the need for substantial additional capital to support ongoing operations and development activities, emphasizing the importance of securing financing to continue its business strategies.